The company decided to move in order to support its ongoing growth and to expand its business.
The headquarters move brings the company to a resident where several healthcare and life science companies reside, thus fulfilling its commitment.
Endo Pharmaceuticals CEO Dave Holvec said they believe this move will undoubtedly send a positive message of growth, stability and promise to their pharmaceutical and business counterparts.
The company’s products and services are utilized to meet the needs of patients in areas such as endocrinology, oncology, pelvic health, pain management and urology.